News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2019

26 March, 2019 Data from the POP study support further development of Aladote® as a new treatment option for reducing liver damage due to paracetamol overdose News Corporate Information Presentation English IR Optional mfn-cus-aladote
26 March, 2019 PledPharma will be presenting company’s drug development programs at today’s CMD in Stockholm News Corporate Information Presentation English IR Optional
18 March, 2019 PledPharma’s drug candidate Aladote® granted Orphan Drug Designation News Corporate Action Other English Regulatory MAR IR Optional mfn-cus-aladote
14 March, 2019 PledPharma Capital Markets Day, March 26 News Corporate Action Other English IR Optional
21 February, 2019 Year-end Report January-December 2018 News English Regulatory MAR Report Interim Yearend IR Optional mfn-cus-aladote mfn-cus-pledox
5 February, 2019 PledPharma Capital Markets Day News Corporate Information Presentation English IR Optional
31 January, 2019 Aladote®’s data has been selected for presentation at The International Liver Congress News English Regulatory IR Optional
17 January, 2019 PledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers Symposium News English Regulatory IR Optional
10 January, 2019 First Asian patient has been included in the global Phase III program for PledOx® and will trigger a milestone payment of 600 MJPY (c.49 MSEK) to PledPharma News English Regulatory IR Optional

2018

24 December, 2018 PledPharma applies for an Orphan Drug Designation (ODD) in the US for Aladote News English Regulatory IR Optional
13 December, 2018 PledPharma presents results from study on drug candidate Aladote® for paracetamol poisoning at a global toxicology conference News English Regulatory IR Optional
5 December, 2018 PledPharma prepares for listing on the Nasdaq Stockholm main market during 2019 News English Regulatory IR Optional
8 November, 2018 The first patient included in PledPharma’s global Phase III program for PledOx® News English Regulatory IR Optional
26 October, 2018 Nomination Committee appointed for the 2019 Annual General Meeting in PledPharma News English Regulatory IR Optional
23 October, 2018 Interim Report January-September 2018 News English Regulatory MAR Report Interim Q3 IR Optional
28 September, 2018 Study drug for the PledOx® global phase III program delivered News English Regulatory IR Optional
24 September, 2018 Pledpharma announces positive results from the Aladote® proof of principle study News English Regulatory IR Optional
22 August, 2018 Half-Year Report January-June 2018 News English Regulatory MAR Report Interim Q2 IR Optional
15 August, 2018 Delivery of study drug to the PledOx® phase III program is expected in September News English Regulatory IR Optional
25 June, 2018 PledPharma establishes a Scientific Advisory Board for the continued clinical development of Aladote® News English IR Optional
25 June, 2018 Aladote® is concluded as safe in first clinical study – PledPharma aims to apply for Orphan Drug Status in the US News English IR Optional
13 June, 2018 Japanese Medical Agency (PMDA) supports the expansion of the Phase III program for PledOx® to include Japanese patients News English IR Optional
14 May, 2018 PledPharma has completed the recruitment for the clinical trial with Aladote® News English IR Optional
24 April, 2018 Interim Report January-March 2018 News English Regulatory MAR Report Interim Q1 IR Optional
28 March, 2018 PledPharma receives European approval of the composition of matter patent for PledOx® and Aladote® News English IR Optional
PreviousNext

Calendar and upcoming reports

August 21, 2026 (7:00am CEST)
Interim Report Q2 2026

September 14-16, 2026
Morgan Stanley 24th Annual Global Healthcare Conference

Show more events

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]